IDEAYA licenses DLL3 ADC SHR-4849 from Hengrui; total potential payments $1.045B

IDEAYA Biosciences, Inc.

Exclusive worldwide license (ex-Greater China) for Phase 1 DLL3-targeting Topo-I-payload ADC SHR-4849.
Hengrui Pharma eligible for $75M upfront, up to $200M development/regulatory milestones, plus commercial milestones and mid-single to low-double digit royalties.
In 11 evaluable SCLC patients at therapeutic doses, 8 partial responses observed (~73% ORR, including unconfirmed) with manageable safety profile.
IDEAYA targets US IND filing for SHR-4849 in H1 2025; cash runway guided to at least 2028 unchanged.
SHR-4849 offers rational combination opportunity with IDEAYA's Phase 1 PARG inhibitor IDE161 for enhanced preclinical efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.